Agilent Technologies is undergoing significant changes in response to market challenges and strategic opportunities, including a planned split into two independent companies aimed at redefining its operational strategy. While the company recently achieved FDA approval for its PD-L1 IHC 22C3 pharmDx assay, significantly bolstering its market position, it currently faces a 12.8% decline in year-to-date performance and lower trading valuations, raising investor concerns. The reliance on fluctuating research and biotech funding cycles further complicates Agilent's outlook, even as it pursues growth by licensing new technologies.
Loading timeline…
